5N Plus keeps Buy rating with Laurentian Bank

Look for better-than-expected third quarter sales from critical materials company 5N Plus (5N Plus Stock Quote, Charts, News, Analysts, Financials TSX:VNP), according to Laurentian Bank Securities analyst Nick Agostino, who delivered an action note to clients on Thursday where he renewed a “Buy” rating on the stock. Agostino said last year’s acquisition of Azur Space should be a big contributor to 5N’s growth.

A producer of specialty metals and chemicals, Montreal-based 5N Plus made a transformational acquisition in April, 2021, of Belgian chemical company MCP, helping to assert 5N as a global refiner of commercial and ultra-high purity metals and compounds for industries such as pharma, electronic, industrial and solar. By material, 5N is the world leading supplier of bismuth and a leader in gallium, germanium, tellurium and indium.

With the company’s Q3 results due on November 1 after market close, Agostino is estimating revenue of $71.2 million compared to the consensus call at $66.5 million and adjusted EBITDA at $7.8 million compared to the Street’s $8.6 million. (All figures in US dollars except where noted otherwise.)

Agostino pointed to recent contract wins for 5N in the form of a renewal from First Solar and a ten-year contract from Sierra Space with VNP’s Azur division. For the third quarter, Agostino is projecting $14.4 million in revenue contribution from Azur, representing about a 12 per cent organic growth rate.

“As VNP reports in US$ but realizes ~42 per cent of sales from Europe and ~21 per cent from Asia, we note the €/US$ depreciated ~4 per cent since Q2 guidance on August 3 which could result in a ~2 per cent (~US$1.5 million) sales headwind, however, this should be neutral for EBITDA given the company has an international cost base,” Agostino wrote.

“We also note encouraging contract momentum with First Solar (FSLR) and Sierra Space that help backfill our 2023 expectations but offer sales / EBITDA / margins accelerated growth potential starting 2024,” he said.

As for commentary from management, Agostino said he’ll be looking for, among others, updates on solar space contracts and on the company’s backlog and bookings as well as any new partnership prospects which could support revenue growth. The analyst also said he’d like to hear about any impact on VNP’s business related to the global chip shortage as well as guidance on organic growth. 

Looking further afield, Agostino is forecasting full 2022 revenue and EBITDA for 5N of $281.5 million and $30.0 million, respectively, and 2023 revenue and EBITDA of $282.0 million and $31.6 million, respectively. With his “Buy” rating, Agostino also reiterated a 12-month target of C$2.50 per share, which at press time represented a projected return of 22 per cent.

Tagged with: vnp
Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Recent Posts

Auxly Cannabis is a winner, this analyst says

Haywood Securities analyst Neal Gilmer raised his target for Auxly Cannabis Group (Auxly Cannabis Group Stock Quote, Chart, News, Analysts,… [Read More]

3 days ago

RBC raises price target on CGI Group to $115.00

RBC Dominion Securities analyst Paul Treiber raised his target for CGI (CGI Stock Quote, Chart, News, Analysts, Financials TSX:GIB.A) to… [Read More]

3 days ago

Why is inflation so bad in Atlantic Canada?

Inflation is running above 3% in eight Canadian provinces, with Atlantic Canada facing some of the strongest price pressures as… [Read More]

3 days ago

Analyst chops target on goeasy (TSX:GSY)

National Bank Financial analyst Jaeme Gloyn lowered his target for goeasy (goeasy Stock Quote, Chart, News, Analysts, Financials TSX:GSY) to… [Read More]

3 days ago

Gain Therapeutics: this analyst just chopped his target

Roth Capital Partners analyst Boobalan Pachaiyappan lowered his target on Gain Therapeutics (Gain Therapeutics Stock Quote, Chart, News, Analysts, Financials… [Read More]

3 days ago

WELLSTAR Technologies is off to a great start, this analyst says

WELLSTAR Technologies’ (WELLSTAR Technologies Corp. Stock Quote, Chart, News, Analysts, Financials TSXV:WSTR) first quarterly results as a public company exceeded… [Read More]

3 days ago